2017

1. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

   The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700